Ricardo Blanco* and Javier Loricera
Volume6-Issue8
Dates: Received: 2025-08-15 | Accepted: 2025-08-29 | Published: 2025-08-30
Pages: 1163-1167
Abstract
FullText HTML
FullText PDF
DOI: 10.37871/jbres2174
Certificate of Publication
Copyright
© 2025 Blanco R, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Blanco R, Loricera J. Tocilizumab Therapy in Giant Cell Arteritis: Insights from Clinical Experience. J Biomed Res Environ Sci. 2025 Aug 30; 6(8): 1163-1167. doi: 10.37871/jbres2174, Article ID: JBRES2174, Available at: https://www.jelsciences. com/articles/jbres2174.pdf
Subject area(s)
References
- Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014 Jul 3;371(1):50-7. doi: 10.1056/NEJMcp1214825. PMID: 24988557; PMCID: PMC4277693.
- Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002 Jul 25;347(4):261-71. doi: 10.1056/NEJMra011913. PMID: 12140303.
- Skaug HK, Fevang BT, Assmus J, Diamantopoulos AP, Myklebust G, Brekke LK. Giant cell arteritis: incidence and phenotypic distribution in Western Norway 2013-2020. Front Med (Lausanne). 2023 Dec 12;10:1296393. doi: 10.3389/fmed.2023.1296393. PMID: 38148911; PMCID: PMC10749960.
- Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, de Miguel E, Ferraz-Amaro I, López-Gutiérrez F, Castañeda S, Loricera J; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. Rheumatology (Oxford). 2025 May 1;64(5):2928-2936. doi: 10.1093/rheumatology/keae666. PMID: 39658241.
- González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, Uriarte E. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998 Aug;41(8):1497-504. doi: 10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z. PMID: 9704651.
- Martín-Gutiérrez A, Molina-Collada J, Domínguez-Álvaro M, Melero-González RB, Fernández-Fernández E, Silva-Díaz M, Valero JA, González I, Martín JS, Narváez J, Calvo I, Aldasoro V, Abasolo Alcázar L, Loricera J, Ruíz-Roman A, Castañeda S, Molina-Almela C, Alcalde Villar M, Juan Mas A, Blanco R; ARTESER Project Collaborative Group. Cerebrovascular accidents in giant cell arteritis: prevalence and predictive factors from the ARTESER registry. Rheumatology (Oxford). 2025 Jun 1;64(6):3733-3738. doi: 10.1093/rheumatology/keaf051. PMID: 39918980.
- Martín-Gutiérrez A, Loricera J, Narváez J, Aldasoro V, Maiz O, Vela P, Romero-Yuste S, de Miguel E, Galíndez-Agirregoikoa E, Fernández-López JC, Ferraz-Amaro I, Sánchez-Martín J, Moya P, Campos C, López-Gutiérrez F, Castañeda S, Blanco R; Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group. Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis. Eur J Intern Med. 2024 Nov;129:78-86. doi: 10.1016/j.ejim.2024.06.013. Epub 2024 Jun 22. PMID: 38908981.
- Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, Bonnotte B. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017 Aug;16(8):833-844. doi: 10.1016/j.autrev.2017.05.014. Epub 2017 May 28. PMID: 28564617.
